Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Evelo Biosciences, Inc.EVLO · Entity 108468 | Director | June 08, 2023 | June 12, 2023 |
| IRONWOOD PHARMACEUTICALS INCIRWD · Entity 5213 | Director | June 16, 2026 | June 17, 2026 |
| Lantheus Holdings, Inc.LNTH · Entity 690 | Director | May 14, 2026 | May 18, 2026 |
| TREVENA INCTRVN · Entity 85383 | Director | May 13, 2020 | May 15, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Evelo Biosciences, Inc.
Report date June 08, 2023 · Filed June 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.11 · Expires 2033-06-08 | Direct | 20,000 |
Reported balance
After 2023-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-08 · Grant · Acquired 20,000 · Balance 20,000 F1: The option vests on the earlier of June 8, 2024, and the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the earlier of June 8, 2024, and the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of the grant.
IRONWOOD PHARMACEUTICALS INC
Report date June 16, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 250,749 |
Ending reported balance
After 2026-06-16 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-16 · Grant · Acquired 63,481 · Balance 272,320 F1: The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Row 2 · 2026-06-16 · Sale · Disposed 21,571 · Balance 250,749 F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.66 to $3.78, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year.
F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.66 to $3.78, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Lantheus Holdings, Inc.
Report date May 14, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,099 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 4,137 · Balance 30,099 |
TREVENA INC
Report date May 13, 2020 · Filed May 15, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.05 · Expires 2030-05-13 | Direct | 64,103 |
Reported balance
After 2020-05-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-13 · Grant · Acquired 64,103 · Balance 64,103 F1: The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AERIE PHARMACEUTICALS INC
Report date November 21, 2022 · Filed November 21, 2022
Section 16 reporting ended · disclosed 2022-11-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-11-21 transaction · row 1
1 source rowRow 1 · 2022-11-21 · Disposition to issuer · Disposed 16,095 · Balance 0 F1: Each of the reported shares of common stock of the Company (each a "Share" or, collectively, the "Shares"), including any Shares of restricted stock, was, at the Effective Time (defined below), cancelled and converted into the right to receive $15.25 in cash (the "Merger Consideration") without interest and subject to any applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.27 · Expires 2030-06-11 | Direct | 0 |
Reported balance
After 2022-11-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-11-21 · Disposition to issuer · Disposed 7,800 · Balance 0 F2: Each stock option with a per Share exercise price that is less than the Merger Consideration was, at the Effective Time, cancelled in exchange for a cash payment equal to, for each Share underlying the stock option (without regard to vesting), the excess of the Merger Consideration over the exercise price payable per Share underlying such stock option. Any stock options with a per Share exercise price that was more than the Merger Consideration were cancelled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.11 · Expires 2032-06-09 | Direct | 0 |
Reported balance
After 2022-11-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-11-21 · Disposition to issuer · Disposed 16,854 · Balance 0 F2: Each stock option with a per Share exercise price that is less than the Merger Consideration was, at the Effective Time, cancelled in exchange for a cash payment equal to, for each Share underlying the stock option (without regard to vesting), the excess of the Merger Consideration over the exercise price payable per Share underlying such stock option. Any stock options with a per Share exercise price that was more than the Merger Consideration were cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Each of the reported shares of common stock of the Company (each a "Share" or, collectively, the "Shares"), including any Shares of restricted stock, was, at the Effective Time (defined below), cancelled and converted into the right to receive $15.25 in cash (the "Merger Consideration") without interest and subject to any applicable withholding taxes.
F2: Each stock option with a per Share exercise price that is less than the Merger Consideration was, at the Effective Time, cancelled in exchange for a cash payment equal to, for each Share underlying the stock option (without regard to vesting), the excess of the Merger Consideration over the exercise price payable per Share underlying such stock option. Any stock options with a per Share exercise price that was more than the Merger Consideration were cancelled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2026 Filed Jun 17, 2026 20:41 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 21,571 | $3.73 | $80,459.83 |
DisclosureSEC source: 0001193125-26-274275 · ownership.xml · nonDerivative · entry 2 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 250,749 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.66 to $3.78, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 16, 2026 Filed Jun 17, 2026 20:41 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 63,481 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-274275 · ownership.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 272,320 F1 · kind: The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:37 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 4,137 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000211 · form4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,099 Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:26 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-085438 · ownership.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 208,839 F1 · kind: The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 20:33 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 5,192 | $81.62 | $423,771.04 |
DisclosureSEC source: 0001062993-25-011413 · form4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,962 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2025. Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:40 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantStock Option (right to buy) · Derivative | 4,543 | $0.00 Strike: $78.81 | $0.00 |
DisclosureSEC source: 0001062993-25-009697 · form4.xml · derivative · entry 2 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,543 Underlying: Common Stock · 4,543 shares Expires 2035-05-14 Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:40 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 2,537 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-009697 · form4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,154 Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 20:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 24,311 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-076210 · ownership.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,839 F1 · kind: The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 20:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 22,766 | $6.29 | $143,198.14 |
DisclosureSEC source: 0000950170-24-072417 · ownership.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,528 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.95 to $6.55, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 28, 2024 Filed May 30, 2024 20:32 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 2,500 | $78.50 | $196,250.00 |
DisclosureSEC source: 0000950170-24-066683 · ownership.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,617 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2024. Read SEC document |
| May 09, 2024 Filed May 13, 2024 21:03 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantStock Option (right to buy) · Derivative | 4,853 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0000950170-24-058814 · ownership.xml · derivative · entry 2 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,853 Underlying: Common Stock · 4,853 shares Expires 2034-05-09 Read SEC document |
| May 09, 2024 Filed May 13, 2024 21:03 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 2,635 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-058814 · ownership.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,117 Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 21:29 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 22,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-039139 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,294 F1 · kind: The restricted stock, granted pursuant to the Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2023, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 16:06 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.11 | $0.00 |
DisclosureSEC source: 0001694665-23-000086 · wk-form4_1686600340.xml · derivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: The option vests on the earlier of June 8, 2024, and the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of the grant. Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:45 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantStock Option (right to buy) · Derivative | 3,798 | $0.00 Strike: $99.38 | $0.00 |
DisclosureSEC source: 0000899243-23-013004 · doc4.xml · derivative · entry 2 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,798 Underlying: Common Stock · 3,798 shares Expires 2033-05-11 Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:45 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 2,012 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-013004 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,482 Read SEC document |
| November 21, 2022 Filed Nov 21, 2022 21:59 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | Disposition to issuerStock Option (right to buy) · Derivative | 16,854 | $9.14 Strike: $6.11 | $154,045.56 |
DisclosureSEC source: 0001209191-22-058191 · doc4.xml · derivative · entry 3 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,854 shares Expires 2032-06-09 F2 · kind: Each stock option with a per Share exercise price that is less than the Merger Consideration was, at the Effective Time, cancelled in exchange for a cash payment equal to, for each Share underlying the stock option (without regard to vesting), the excess of the Merger Consideration over the exercise price payable per Share underlying such stock option. Any stock options with a per Share exercise price that was more than the Merger Consideration were cancelled for no consideration. F2 · derivative.exercise_date: Each stock option with a per Share exercise price that is less than the Merger Consideration was, at the Effective Time, cancelled in exchange for a cash payment equal to, for each Share underlying the stock option (without regard to vesting), the excess of the Merger Consideration over the exercise price payable per Share underlying such stock option. Any stock options with a per Share exercise price that was more than the Merger Consideration were cancelled for no consideration. Read SEC document |
| November 21, 2022 Filed Nov 21, 2022 21:59 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | Disposition to issuerStock Option (right to buy) · Derivative | 7,800 | $1.98 Strike: $13.27 | $15,444.00 |
DisclosureSEC source: 0001209191-22-058191 · doc4.xml · derivative · entry 2 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,800 shares Expires 2030-06-11 F2 · kind: Each stock option with a per Share exercise price that is less than the Merger Consideration was, at the Effective Time, cancelled in exchange for a cash payment equal to, for each Share underlying the stock option (without regard to vesting), the excess of the Merger Consideration over the exercise price payable per Share underlying such stock option. Any stock options with a per Share exercise price that was more than the Merger Consideration were cancelled for no consideration. F2 · derivative.exercise_date: Each stock option with a per Share exercise price that is less than the Merger Consideration was, at the Effective Time, cancelled in exchange for a cash payment equal to, for each Share underlying the stock option (without regard to vesting), the excess of the Merger Consideration over the exercise price payable per Share underlying such stock option. Any stock options with a per Share exercise price that was more than the Merger Consideration were cancelled for no consideration. Read SEC document |
| November 21, 2022 Filed Nov 21, 2022 21:59 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | Disposition to issuerCommon Stock | 16,095 | $15.25 | $245,448.75 |
DisclosureSEC source: 0001209191-22-058191 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Each of the reported shares of common stock of the Company (each a "Share" or, collectively, the "Shares"), including any Shares of restricted stock, was, at the Effective Time (defined below), cancelled and converted into the right to receive $15.25 in cash (the "Merger Consideration") without interest and subject to any applicable withholding taxes. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 20:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 4,300 | $78.50 | $337,550.00 |
DisclosureSEC source: 0000899243-22-030671 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,470 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2022. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 16:48 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001694665-22-000104 · wf-form4_165515327929416.xml · derivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The option vests on the earlier of June 9, 2023 and the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 21:21 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | GrantStock Option (right to buy) · Derivative | 16,854 | $0.00 Strike: $6.11 | $0.00 |
DisclosureSEC source: 0001209191-22-036403 · doc4.xml · derivative · entry 2 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,854 Underlying: Common Stock · 16,854 shares Expires 2032-06-09 F2 · derivative.exercise_date: Subject to the reporting person's continued service on the board of directors of the issuer through the applicable vesting date, this option is scheduled to vest ratably on each of the first 12 monthly anniversaries of June 9, 2022. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 21:21 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | GrantCommon Stock | 6,245 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-036403 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,095 F1 · shares: Subject to the reporting person's continued service on the board of directors of the issuer through the vesting date, these shares of Common Stock are scheduled to vest on June 9, 2023. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:06 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 21,571 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-033973 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,944 F1 · kind: The restricted stock, granted pursuant to the Director Compensation Policy effective May 2019, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document |
| May 11, 2022 Filed May 13, 2022 20:31 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 2,980 | $57.84 | $172,363.20 |
DisclosureSEC source: 0000899243-22-018014 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,770 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2022. Read SEC document |
| May 06, 2022 Filed May 10, 2022 20:40 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantStock Option (right to buy) · Derivative | 3,616 | $0.00 Strike: $64.20 | $0.00 |
DisclosureSEC source: 0000899243-22-017445 · doc4.xml · derivative · entry 2 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,616 Underlying: Common Stock · 3,616 shares Expires 2032-05-06 Read SEC document |
| May 06, 2022 Filed May 10, 2022 20:40 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 2,180 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-017445 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,750 F1 · shares: The restricted stock units cliff vest on May 6, 2023. Read SEC document |
| May 06, 2022 Filed May 12, 2022 21:47 UTC Amendment | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantStock Option (right to buy) · Derivative | 4,068 | $0.00 Strike: $64.20 | $0.00 |
DisclosureSEC source: 0000899243-22-017797 · doc4a.xml · derivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,068 Underlying: Common Stock · 4,068 shares Expires 2032-05-06 F1 · shares: The Form 4 originally filed on May 10, 2022 inadvertently reported 3,616 options granted on May 6, 2022 due to an administrative error. The correct amount of options granted on May 6, 2022 is 4,068 and is being reported in this amendment. F1 · derivative.underlying_shares: The Form 4 originally filed on May 10, 2022 inadvertently reported 3,616 options granted on May 6, 2022 due to an administrative error. The correct amount of options granted on May 6, 2022 is 4,068 and is being reported in this amendment. F1 · balance_after: The Form 4 originally filed on May 10, 2022 inadvertently reported 3,616 options granted on May 6, 2022 due to an administrative error. The correct amount of options granted on May 6, 2022 is 4,068 and is being reported in this amendment. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 20:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 20,000 | $11.67 | $233,400.00 |
DisclosureSEC source: 0001209191-22-019205 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,373 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.55 to $11.77, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 21:06 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleCommon Stock | 10,000 | $11.02 | $110,200.00 |
DisclosureSEC source: 0001209191-21-069945 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,373 Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:21 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | GrantStock Option (right to buy) · Derivative | 7,800 | $0.00 Strike: $16.21 | $0.00 |
DisclosureSEC source: 0001209191-21-041989 · doc4.xml · derivative · entry 2 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2031-06-17 F2 · derivative.exercise_date: Subject to the reporting person's continued service on the board of directors of the issuer through the applicable vesting date, this option is scheduled to vest ratably on each of the first 12 monthly anniversaries of June 17, 2021. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:21 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | GrantCommon Stock | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-041989 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,850 F1 · shares: Subject to the reporting person's continued service on the board of directors of the issuer through the vesting date, these shares of Common Stock are scheduled to vest on June 17, 2022. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 20:13 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 22,766 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038199 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,373 F1 · kind: The restricted stock, granted pursuant to the Director Compensation Policy effective May 2019, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document |
| May 10, 2021 Filed May 12, 2021 20:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 8,513 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-019270 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,570 Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 20:02 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-027938 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,607 F1 · kind: The restricted stock, granted in connection with additional time the reporting person is spending providing counsel and guidance to the Company's senior leadership team during the chief executive officer transition period, vests in full on March 15, 2022. Read SEC document |
| April 09, 2021 Filed Apr 13, 2021 16:56 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | GrantStock Option (Right to Buy) · Derivative | 31,380 | $0.00 Strike: $10.04 | $0.00 |
DisclosureSEC source: 0001694665-21-000051 · wf-form4_161834738814163.xml · derivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,380 Underlying: Common Stock · 31,380 shares Expires 2031-04-08 F1 · derivative.exercise_date: The option vests in 36 substantially equal monthly installments following the grant date and has a term of 10 years. Read SEC document |
| April 09, 2021 Filed Apr 13, 2021 20:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 2,800 | $21.22 | $59,416.00 |
DisclosureSEC source: 0000899243-21-015614 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,057 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2021. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:50 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 1,259 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027271 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,857 F1 · kind: As previously disclosed, the Board of Directors of the Company elected to receive all remaining compensation payable in 2020 in the form of time-based restricted stock units, rather than in cash. The transaction reported in this Form 4 reports the additional restricted stock units earned by the reporting person for the compensation payable in the fourth quarter of 2020, as calculated by the Company on October 1, 2020. Read SEC document |
| September 08, 2020 Filed Sep 9, 2020 22:26 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 7,950 | $9.77 | $77,671.50 |
DisclosureSEC source: 0001209191-20-049868 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,107 F1 · kind: This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and was effected to cover tax withholding obligations in connection with the vesting of the reporting person's director restricted stock awards. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.53 to $9.92, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 21:36 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 749 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-022149 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,598 F1 · kind: As previously disclosed, including most recently in our Form 10-Q for the fiscal period ended June 30, 2020, the Board of Directors of the Company elected to receive all remaining compensation payable in 2020 in the form of time-based restricted stock units, rather than in cash. The transaction reported in this Form 4 reports the additional restricted stock units earned by the reporting person for the compensation payable in the third quarter of 2020, as finally calculated by the Company on August 10, 2020. Read SEC document |
| June 11, 2020 Filed Jun 30, 2020 00:01 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | GrantStock Option (right to buy) · Derivative | 7,800 | $0.00 Strike: $13.27 | $0.00 |
DisclosureSEC source: 0001209191-20-039258 · doc4.xml · derivative · entry 2 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2030-06-11 F2 · derivative.exercise_date: Subject to the reporting person's continued service on the board of directors of the issuer through the applicable vesting date, this option is scheduled to vest ratably on each of the first 12 monthly anniversaries of June 11, 2020. Read SEC document |
| June 11, 2020 Filed Jun 30, 2020 00:01 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | GrantCommon Stock | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-039258 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,100 F1 · shares: Subject to the reporting person's continued service on the board of directors of the issuer through the vesting date, these shares of Common Stock are scheduled to vest on June 11, 2021. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 20:35 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 21,720 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034696 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,057 F1 · kind: The restricted stock, granted pursuant to the Director Compensation Policy effective May 2019, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document |
| May 13, 2020 Filed May 15, 2020 21:24 UTC | TREVENA INC TRVN · Entity 85383 | GrantStock Option (Right to Buy) · Derivative | 64,103 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001209191-20-029775 · doc4.xml · derivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,103 Underlying: Common Stock · 64,103 shares Expires 2030-05-13 F1 · derivative.exercise_date: The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 21:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 8,095 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-007196 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,849 Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 21:34 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 1,756 | $15.86 | $27,844.89 |
DisclosureSEC source: 0000899243-20-006494 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,754 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.58 to $16.10, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc., ("LNTH") any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 20:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 1,500 | $11.26 | $16,890.00 |
DisclosureSEC source: 0001209191-19-035509 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,337 F1 · kind: This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and was effected to cover tax withholding obligations in connection with the vesting of the reporting person's director restricted stock awards. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.15 to $11.37, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:12 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 22,706 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-033630 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,837 F1 · kind: The restricted stock, granted pursuant to the director compensation policy, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document |
| May 23, 2019 Filed May 23, 2019 22:16 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | GrantStock Option (right to buy) · Derivative | 7,800 | $0.00 Strike: $39.44 | $0.00 |
DisclosureSEC source: 0001209191-19-032437 · doc4.xml · derivative · entry 2 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2029-05-23 F2 · derivative.exercise_date: Subject to the reporting person's continued service on the board of directors of the issuer through the applicable vesting date, this option is scheduled to vest ratably on each of the first 12 monthly anniversaries of May 23, 2019. Read SEC document |
| May 23, 2019 Filed May 23, 2019 22:16 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | GrantCommon Stock | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-032437 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,350 F1 · shares: Subject to the reporting person's continued service on the board of directors of the issuer through the vesting date, these shares of Common Stock are scheduled to vest on May 23, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.